Merck Has The Best Anti-Cancer Portfolio - Cramer's Lightning Round (7/6/18)

by: SA Editor Mohit Manghnani

Cara Therapeutics is a good buy.

Stay away from Annaly Capital Management.

Accounting irregularities equal to sell.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, July 6.

Bullish Calls

Cara Therapeutics (NASDAQ:CARA): The stock is back to $20, and Cramer had recommended it at $17-18. It's a good buy here.

Merck & Co. (NYSE:MRK): It has the best anti-cancer portfolio, and the company is not promotional. The stock yields 3%, and Cramer likes it.

IBM Corp. (NYSE:IBM): Buy half now and half when it goes lower. The 4.4% yield is good, and Cramer expects the next earnings quarter to be okay.

FactSet Research Systems (NYSE:FDS): "You’ve got smart money because I like that stock. I wish more people liked it. I’d put that in the fintech category. Boy, do people love fintech."

Bearish Calls

Yirendai (NYSE:YRD): Cramer does not want to recommend Chinese stocks other than Alibaba (NYSE:BABA) and Baidu (NASDAQ:BIDU).

Annaly Capital Management (NYSE:NLY): It has a big yield, but the company is opaque. Cramer does not recommend it.

SMART Global Holdings (NASDAQ:SGH): Cramer thinks HP, Inc. (NYSE:HPQ) is a much better buy.

PPG Industries (NYSE:PPG): Out of discipline, Cramer does not buy stocks of companies with accounting irregularities.


Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up